← Leaderboards
Benjamin Reisman
Vanderbilt University
$116,729
Attributed
$116,729
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46.8K · FY2019–21$50K$37.5K$25K$12.5K$0
'19
'20
'21
Funding mix
By agency
NIH$116,729 · 1
By mechanism
F30$116,729 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Eugene M. Oltz$20,457,685
- Dean Ballard$6,316,793
- Srividya Bhaskara$1,831,676
- Lawrence J Marnett$28,791,111
Others in their field
Other Emerging Leaders on “Acute Myelocytic Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,430,568
- Crystal Mackall · Children'S Hosp Of Philadelphia$6,450,142
- Christopher A Miller · Washington University$5,424,298
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Kelly Diringer Getz · University Of Pennsylvania$4,068,250
Research focus
Acute Myelocytic LeukemiaAffinityAffinity ChromatographyAffectAnalogApoptolidinApoptosis In LymphocytesAzidesBacteriaBaseBioactive Natural ProductsBiologicalBiological ModelsBiological SystemsBlood CellsCancerousCellsCell TypeCoupledCytometryCytotoxicCytotoxicityDrug DiscoveryDysmyelopoietic Syndromes
Grant awards (3)
Differentiation-Dependent Targeting of Glycosylated Polyketides in Clonal Hematopoietic Disorders$40,271
F30 · FY2021 · CA · contact PI
Differentiation-Dependent Targeting of Glycosylated Polyketides in Clonal Hematopoietic Disorders$46,762
F30 · FY2020 · CA · contact PI
Differentiation-Dependent Targeting of Glycosylated Polyketides in Clonal Hematopoietic Disorders$29,696
F30 · FY2019 · CA · contact PI